EGFR and colorectal carcinoma: However, methylation of histone H3 lysine residues 9 and 27 inhibits EGFR transcription, and treatment with inhibitors targeting KDM4 (a demethylase for H3K9/36) can decrease EGFR amplification, consequently overcoming drug resistance to cetuximab in advanced CRC patients to some extent [13,14].